P450: PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS
Main Authors: | U. Pakulska, N. Angelosanto, M. Mikula, H. Nogai, R. Dudziak, C. Abboud, M. Obacz, K. Goller, M. Cybulska, M. Mazan, M. Kozakowska, T. Rzymski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000844688.25652.68 |
Similar Items
-
P501: CLI120-001 PHASE1B DOSE ESCALATION STUDY OF RVU120 IN PATIENTS WITH AML OR HIGH RISK MDS SAFETY AND EFFICACY DATA UPDATE
by: C. Abboud, et al.
Published: (2022-06-01) -
Inherited predisposition to MDS/AML
by: Ana Rio Machin, et al.
Published: (2018-06-01) -
Alignment of RVU Targets With Operating Room Block Time
by: Saieesh A. Rao, MD, et al.
Published: (2023-03-01) -
PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML
by: Barbara De Moerloose
Published: (2023-12-01) -
Gene expression profiling in MDS and AML: potential and future avenues.
by: Theilgaard-Mönch, K, et al.
Published: (2011)